Tiziana Life Sciences Ltd. (TLSA)
NASDAQ
$1.01−$0.0300 (−2.88%) on the dayAs of the close; data may be delayed.
TLSA price, last 12 months
Key stats
- Previous close
- $1.04
- Open
- $1.02
- Day range
- $1.00 – $1.08
- 52-week range
- $0.7615 – $2.35
- Volume
- 372.5K
- Avg volume (20 days)
- 639.2K
- Market cap
- $128.5M
Performance
1W+11.5%
1M−7.3%
3M−14.4%
6M−19.2%
YTD−32.2%
1Y−48.7%
vs S&P 500, 1Y−65.5 pts
Technicals and fundamentals
About Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
- Listed on
- NASDAQ
- Market cap
- $128.5M